$ESPR
Esperion Therapeutics, Inc.

2013 Q3 Form 10-Q Financial Statement

#000110465913062514 Filed on August 12, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2013 Q2 2012 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.900M $1.200M $500.0K
YoY Change 280.0% 140.0%
% of Gross Profit
Research & Development $3.483M $3.100M $2.330M
YoY Change 41.78% 33.03%
% of Gross Profit
Depreciation & Amortization $10.00K $20.00K $30.00K
YoY Change -75.0% -33.33%
% of Gross Profit
Operating Expenses $5.407M $4.272M $2.864M
YoY Change 80.82% 49.17%
Operating Profit -$5.407M -$4.272M -$2.864M
YoY Change 80.82% 49.17%
Interest Expense $0.00 $108.0K $303.2K
YoY Change -100.0% -64.38%
% of Operating Profit
Other Income/Expense, Net $168.4K $4.000K $894.00
YoY Change 41892.27% 347.43%
Pretax Income -$5.200M -$6.900M -$3.200M
YoY Change 52.94% 115.63%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.238M -$6.921M -$3.166M
YoY Change 56.31% 118.59%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$339.9K -$23.00M -$10.67M
COMMON SHARES
Basic Shares Outstanding 15.36M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q3 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $71.90M $16.60M
YoY Change
Cash & Equivalents $71.90M $16.63M $2.050M
Short-Term Investments
Other Short-Term Assets $1.000M $2.800M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $72.96M $19.39M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $78.75K $89.27K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $13.50M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $13.61M $145.0K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $72.96M $19.39M
Total Long-Term Assets $13.61M $145.0K
Total Assets $86.58M $19.53M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.945M $1.656M
YoY Change
Accrued Expenses $1.400M $2.100M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.343M $6.644M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.343M $6.644M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $3.343M $6.644M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $15.36K $396.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $83.23M -$52.34M
YoY Change
Total Liabilities & Shareholders Equity $86.58M $19.53M
YoY Change

Cashflow Statement

Concept 2013 Q3 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$5.238M -$6.921M -$3.166M
YoY Change 56.31% 118.59%
Depreciation, Depletion And Amortization $10.00K $20.00K $30.00K
YoY Change -75.0% -33.33%
Cash From Operating Activities -$4.770M -$3.180M -$2.840M
YoY Change 63.92% 11.97%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$20.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$13.39M $60.00K $0.00
YoY Change -134000.0%
Cash From Investing Activities -$13.39M $40.00K $0.00
YoY Change -134000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 73.44M 15.88M 20.00K
YoY Change 1726.87% 79300.0%
NET CHANGE
Cash From Operating Activities -4.770M -3.180M -2.840M
Cash From Investing Activities -13.39M 40.00K 0.000
Cash From Financing Activities 73.44M 15.88M 20.00K
Net Change In Cash 55.28M 12.74M -2.820M
YoY Change 4835.71% -551.77%
FREE CASH FLOW
Cash From Operating Activities -$4.770M -$3.180M -$2.840M
Capital Expenditures $0.00 -$20.00K $0.00
Free Cash Flow -$4.770M -$3.160M -$2.840M
YoY Change 63.92% 11.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-32.09
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.47
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7312441 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-41364703 USD
CY2012Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
41975025 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
609976 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
346 USD
CY2012Q4 us-gaap Liabilities
Liabilities
24702144 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17173299 USD
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
210329 USD
CY2012Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
265323 USD
CY2012Q4 espr Accrued Clinical Development Costs Current
AccruedClinicalDevelopmentCostsCurrent
242171 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
476277 USD
CY2012Q4 us-gaap Interest Payable Current
InterestPayableCurrent
738192 USD
CY2012Q4 us-gaap Assets
Assets
7312441 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
120210 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
7138406 USD
CY2012Q4 us-gaap Assets Held For Sale Current
AssetsHeldForSaleCurrent
109344 USD
CY2012Q4 espr Other Prepaid Expense And Assets Current
OtherPrepaidExpenseAndAssetsCurrent
150325 USD
CY2012Q4 espr Prepaid Clinical Development Costs Current
PrepaidClinicalDevelopmentCostsCurrent
367216 USD
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19534137 USD
us-gaap Operating Expenses
OperatingExpenses
46565028 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13872540 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
32606876 USD
us-gaap Revenue From Grants
RevenueFromGrants
244479 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1953 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-5053464 USD
us-gaap Operating Expenses
OperatingExpenses
5053464 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1166030 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3887434 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20949 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2586865 USD
CY2012Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
894 USD
CY2013Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2544907 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7615859 USD
us-gaap Operating Expenses
OperatingExpenses
7615859 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2422844 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5193015 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2863881 USD
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
-52338374 USD
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
396414 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
313258 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-42020568 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
4592 USD
CY2013Q2 us-gaap Assets
Assets
19534137 USD
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
533658 USD
CY2012Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2330223 USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2049679 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1571084 USD
CY2013Q2 us-gaap Assets Current
AssetsCurrent
19389123 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6511521 USD
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
346478 shares
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
372079 shares
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
478595 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
6017362 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
6000000 USD
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-17.92
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
347831 shares
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4271847 USD
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
2863881 USD
CY2013Q2 us-gaap Liabilities
Liabilities
6644425 USD
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6644425 USD
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
346478 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
4271847 USD
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
318654 shares
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.94
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
60465 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-46320549 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6168 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10668 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
4500 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5532599 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-203697 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
11641 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
394930 USD
us-gaap Share Based Compensation
ShareBasedCompensation
31299 USD
us-gaap Depreciation
Depreciation
71956 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
10115338 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
15883392 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
38062 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5806116 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
16626859 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
55628915 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
3018512 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10219064 shares
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7351778 shares
espr Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
0 USD
espr Fair Value Measurement Liability Transfers Between Levels
FairValueMeasurementLiabilityTransfersBetweenLevels
0 USD
espr Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
0 USD
espr Fair Value Measurement Liability Transfers Between Levels
FairValueMeasurementLiabilityTransfersBetweenLevels
0 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
211500 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.43
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
674040 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
540126 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.73
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.15
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y10M24D
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
7662092 USD
CY2013Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6453501 USD
CY2013Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1100944 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-6921076 USD
us-gaap Net Income Loss
NetIncomeLoss
-53135278 USD
espr Amortization Of Debt Discount Premium And Beneficial Conversion
AmortizationOfDebtDiscountPremiumAndBeneficialConversion
458993 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-29000 USD
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
1949 USD
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q2 espr Prepaid Clinical Development Costs Current
PrepaidClinicalDevelopmentCostsCurrent
212612 USD
CY2013Q2 espr Other Prepaid Expense And Assets Current
OtherPrepaidExpenseAndAssetsCurrent
70907 USD
CY2013Q2 us-gaap Assets Held For Sale Current
AssetsHeldForSaleCurrent
29108 USD
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
89274 USD
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1655762 USD
CY2013Q2 espr Accrued Clinical Development Costs Current
AccruedClinicalDevelopmentCostsCurrent
923809 USD
CY2013Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2852188 USD
CY2013Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1212666 USD
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
396 USD
CY2013Q2 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
53135278 USD
CY2008Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000 shares
CY2008Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
44025145 shares
CY2008Q2 espr Number Of New Series Preferred Stock Authorized
NumberOfNewSeriesPreferredStockAuthorized
2 item
CY2010Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45025145 shares
CY2011Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
58220375 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75220375 shares
dei Entity Registrant Name
EntityRegistrantName
Esperion Therapeutics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001434868
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15357413 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
56519253 shares
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7528845 USD
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2012Q4 espr Short Term Borrowings Related Party Net
ShortTermBorrowingsRelatedPartyNet
15241007 USD
us-gaap Net Income Loss
NetIncomeLoss
-5615106 USD
us-gaap Net Income Loss
NetIncomeLoss
-11160253 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-3166154 USD
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
796508 USD
CY2013Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3100422 USD
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1171425 USD
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
85612 USD
CY2013Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4035 USD
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-19.82
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
349170 shares
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2554498 USD
us-gaap Depreciation
Depreciation
49139 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
18533 USD
us-gaap Share Based Compensation
ShareBasedCompensation
153412 USD
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
5029 USD
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
23488 USD
us-gaap Share Based Compensation
ShareBasedCompensation
410520 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
4400 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-324701 USD
us-gaap Depreciation
Depreciation
1426310 USD
espr Amortization Of Debt Discount Premium And Beneficial Conversion
AmortizationOfDebtDiscountPremiumAndBeneficialConversion
575981 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
33911 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-213574 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
287695 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1102900 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
323196 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
763972 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1555397 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
56265 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18203 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-50626 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
285762 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
31569166 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
31515350 USD
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
2500000 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
807464 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
15412010 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
123245 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
17362 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
184068 USD
CY2012Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
53825 USD
CY2013Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
55740 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
1.54
us-gaap Interest Expense
InterestExpense
563595 USD
us-gaap Interest Expense
InterestExpense
936580 USD
CY2012Q2 us-gaap Interest Expense
InterestExpense
303167 USD
us-gaap Interest Expense
InterestExpense
4320696 USD
CY2013Q2 us-gaap Interest Expense
InterestExpense
108357 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
459055 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
563595 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
3726092 USD
espr Proceeds From Issuance Of Warrants Fair Value Estimate
ProceedsFromIssuanceOfWarrantsFairValueEstimate
297690 USD
espr Proceeds From Issuance Of Preferred Stock And Preference Stock Net Of Issuance Costs
ProceedsFromIssuanceOfPreferredStockAndPreferenceStockNetOfIssuanceCosts
16826994 USD
espr Proceeds From Issuance Of Preferred Stock And Preference Stock Net Of Issuance Costs
ProceedsFromIssuanceOfPreferredStockAndPreferenceStockNetOfIssuanceCosts
40801994 USD
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
706040 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
545549 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1073 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
49936 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.74
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.23
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8018165 USD

Files In Submission

Name View Source Status
0001104659-13-062514-index-headers.html Edgar Link pending
0001104659-13-062514-index.html Edgar Link pending
0001104659-13-062514.txt Edgar Link pending
0001104659-13-062514-xbrl.zip Edgar Link pending
a13-16335_110q.htm Edgar Link pending
a13-16335_1ex10d1.htm Edgar Link pending
a13-16335_1ex31d1.htm Edgar Link pending
a13-16335_1ex32d1.htm Edgar Link pending
espr-20130630.xml Edgar Link completed
espr-20130630.xsd Edgar Link pending
espr-20130630_cal.xml Edgar Link unprocessable
espr-20130630_def.xml Edgar Link unprocessable
espr-20130630_lab.xml Edgar Link unprocessable
espr-20130630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending